7Baggers

Kazia Therapeutics Quarterly Income Statements Chart

Quarterly
 | 
Annual
 
 Revenue  
 Gross Profit  
 Operating Profit  
 Net Income  
20171231 20180331 20180630 20180930 20181231 20190331 20190630 20190930 20191231 20200331 20200630 20200930 20201231 20210331 20210630 20210930 20211231 20220630 20230331 20230630 -13.45-9.36-5.27-1.182.91711.0915.18Milllion

Kazia Therapeutics Quarterly Income Statements Table

Quarterly
 | 
Annual
 
Unit: USD2023-06-30 2023-03-31 2022-06-30 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2008-06-30 2008-03-31 2007-12-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-12-31 2004-09-30 2004-06-30 2004-03-31 2003-12-31 2003-09-30 2003-06-30 2003-03-31 2003-03-05 2002-12-31 2002-09-30 2002-06-30 2002-03-31 2001-12-31 2001-09-30 2001-06-30 2001-03-31 2000-12-31 2000-09-30 2000-06-30 2000-03-31 1999-12-31 1999-09-30 
  revenue555 278 -2,898,302.8 10,000 5,000 15,181,541 7,590,771 1,170 585 362,429 181,214 625,681 312,841 671,756 335,878 768,244 384,122 1,554,908 777,454 1,449,295 724,648 4,201,698 2,100,849 4,586,539 2,293,270 236,087 118,043 3,035,799 1,517,900 129,149 64,574 1,589,161 794,581 399,465 199,733 29,206 14,603 253,688 248,247 610,001 305,001 2,897,742 3,540,239 3,414,507 3,416,284 3,416,254 3,404,494 5,250,813 5,237,836 2,426,505 2,433,017 4,325,171 4,325,944 7,213,018 3,036,376 4,799,741 4,794,897 4,572,940 4,094,151 4,110,040 4,111,769 19,051,498 4,910,206 4,910,206.98 4,908,626 4,908,370 4,878,192 4,904,398 4,897,650 4,896,557 12,423,497 15,496,939 13,493,700 13,844,171 -2,126,119.5 9,624,199 8,945,308 8,969,243 
  cost of revenue2,898,302 2,883,144 9,851,428 9,850,924 9,839,381 9,852,489 5,781,489 1,156,747 1,199,615 
  gross profit555 278 -5,796,604.8 10,000 5,000 12,298,396 7,590,771 1,170 585 -9,488,999.11 181,214 625,681 312,841 -9,179,168.11 335,878 768,244 384,122 -8,284,473.11 777,454 1,449,295 724,648 -5,650,791.11 2,100,849 4,586,539 2,293,270 -5,545,402.11 118,043 3,035,799 1,517,900 129,149 64,574 1,589,161 794,581 399,465 199,733 29,206 14,603 253,688 248,247 610,001 305,001 2,897,742 3,540,239 3,414,507 3,416,284 3,416,254 3,404,494 5,250,813 5,237,836 2,426,505 2,433,017 3,168,424 4,325,944 7,213,018 3,036,376 3,600,126 4,794,897 4,572,940 4,094,151 4,110,040 4,111,769 19,051,498 4,910,206 4,910,206.98 4,908,626 4,908,370 4,878,192 4,904,398 4,897,650 4,896,557 12,423,497 15,496,939 13,493,700 13,844,171 -2,126,119.5 9,624,199 8,945,308 8,969,243 
  operating expenses                                                                              
  research and development6,204,098 3,102,049 9,180,556 10,988,075 5,494,038 11,681,825 5,840,912 2,859,541 1,429,771 5,298,936 2,649,468 4,195,392 2,097,696 2,767,022 1,383,511 3,707,978 1,853,989 5,077,288 2,538,644 4,696,374 2,348,187 6,255,347 3,127,673 4,880,831 2,440,416 4,883,054 2,441,527 5,010,928 2,505,464 3,341,590 1,670,795 2,593,767 1,296,884 2,731,823 1,365,911 596,625 298,313 128,205 927,000 2,458,260 2,310,796 
  sales, general and administrative                                                                              
  total operating expenses7,037,673 3,518,836 11,864,417 13,529,811 6,764,906 17,586,606 8,793,304 6,544,652 3,272,326 7,131,150 3,565,575 6,688,525 3,344,264 5,162,463 2,581,231 6,945,537 3,472,769 8,180,380 4,090,191 1,168,252 584,125 10,822,750 5,411,375 8,834,132 4,417,067 8,556,968 4,278,484 6,869,408 3,434,705 4,993,399 2,496,700 3,962,336 1,981,168 4,322,857 2,161,429 2,960,015 1,480,006 951,204 1,011,612 591,473 295,737 -10,090,701.6 10,090,701 -44,329,220.4 12,740,385 3,015,000 -35,808,958.24 6,937,756 -29,779,775.77 6,150,590 -28,730,636.52 -43,428,318.9 -38,593,273.13 -100,824,923.09 -40,401,937.8 
  operating income-10,510,041 -5,255,021 -11,938,528 -13,445,701 -6,722,851 55,649 27,825 -6,433,935 -3,216,968 -6,519,488 -3,259,744 -5,674,338 -2,837,169 -3,769,274 -1,884,637 -5,025,726 -2,512,863 -4,661,256 -2,330,628 -7,698,216 -3,849,108 -6,596,836 -3,298,418 -4,255,924 -2,127,962 -7,308,538 -3,654,269 -5,055,954 -2,527,977 -5,534,983 -2,767,492 -2,517,848 -1,258,924 -3,953,270 -1,976,635 -2,361,030 -1,180,515 -695,091 -700,532 -599,267 -299,634 -36,206,698.93 3,540,239 -6,676,194.3 3,416,284 -40,912,966.4 3,404,494 -7,489,571.6 5,237,836 -33,382,453.24 2,433,017 -3,769,332 4,325,944 -22,566,757.77 3,036,376 -2,550,463.6 4,794,897 -24,157,696.52 4,094,151 4,110,040 4,111,769 -24,376,820.9 4,910,206 4,910,206.98 4,908,626 4,908,370 -33,715,081.13 4,904,398 4,897,650 4,896,557 -88,401,426.09 15,496,939 13,493,700 13,844,171 -42,528,057.3 9,624,199 8,945,308 8,969,243 
  net income-6,879,153 -3,439,576 -11,812,207 -13,201,848 -6,600,924 -2,058,399 -1,029,199 -6,363,560 -3,181,780 -6,586,281 -3,293,140 -5,881,185 -2,940,593 -4,241,805 -2,120,902 -6,028,195 -3,014,098 -6,464,021 -3,232,011 424,779 212,390 -6,487,821 -3,243,911 -4,182,556 -2,091,278 -8,229,051 -4,114,525 -3,833,605 -1,916,803 -4,891,189 -2,445,594 -2,247,407 -1,123,704 -4,412,056 -2,206,028 -3,055,263 -1,527,632 -763,364 -763,365 -227,764 -113,882 -4,369,672.51 -5,348,160.51 -5,869,896.15 -5,872,090 -4,727,190.6 -4,713,630.6 -5,285,041.3 -5,272,665.6 -4,831,155.84 -4,840,851.4 -3,279,045.7 -3,279,260.16 -3,706,996.59 -3,782,198.43 -2,346,682.84 -2,565,799.43 -3,497,813.49 -3,131,895.74 -3,143,988.12 -3,144,121.42 -1,705,775.76 -2,902,764.76 -2,902,764.76 -3,127,399.54 -3,230,499.66 -3,638,883.4 -3,674,549.2 -3,669,319.38 -3,669,375.6 -8,993,646.54 -11,218,580.26 -9,768,390.53 -10,022,104.36 44,975,781 -19,551,004.8 -18,171,877.92 -18,220,499.84 

We provide you with 20 years income statements for Kazia Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Kazia Therapeutics stock. Explore the full financial landscape of Kazia Therapeutics stock with our expertly curated income statements.

The information provided in this report about Kazia Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.